May 7th, 2019, FDA grants FTD for Leronlimab (PRO1
Post# of 148158
(Total Views: 443)
Posted On: 10/04/2021 12:04:44 AM
May 7th, 2019, FDA grants FTD for Leronlimab (PRO140), on Metastatic triple-negative breast cancer, an unmet need.
Drugs.com update by Judith Stewart BPharm on August 31, 2021. WE should post this as it provides a timeline for LeronLimab on indications, since 05/07/19.
Drugs.com update by Judith Stewart BPharm on August 31, 2021. WE should post this as it provides a timeline for LeronLimab on indications, since 05/07/19.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼